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ABSTRACT During 2015 to 2016, Brazil reported more Zika virus (ZIKV) cases than
any other country, yet population exposure remains unknown. Serological studies of
ZIKV are hampered by cross-reactive immune responses against heterologous vi-
ruses. We conducted serosurveys for ZIKV, dengue virus (DENV), and Chikungunya
virus (CHIKV) in 633 individuals prospectively sampled during 2015 to 2016, includ-
ing microcephaly and non-microcephaly pregnancies, HIV-infected patients, tubercu-
losis patients, and university staff in Salvador in northeastern Brazil using enzyme-
linked immunosorbent assays (ELISAs) and plaque reduction neutralization tests. Sera
sampled retrospectively during 2013 to 2015 from 277 HIV-infected patients were
used to assess the spread of ZIKV over time. Individuals were georeferenced, and so-
ciodemographic indicators were compared between ZIKV-positive and -negative ar-
eas and areas with and without microcephaly cases. Epidemiological key parameters
were modeled in a Bayesian framework. ZIKV seroprevalence increased rapidly dur-
ing 2015 to 2016, reaching 63.3% by 2016 (95% conﬁdence interval [CI], 59.4 to
66.8%), comparable to the seroprevalence of DENV (75.7%; CI, 69.4 to 81.1%) and
higher than that of CHIKV (7.4%; CI, 5.6 to 9.8%). Of 19 microcephaly pregnancies,
94.7% showed ZIKV IgG antibodies, compared to 69.3% of 257 non-microcephaly
pregnancies (P  0.017). Analyses of sociodemographic data revealed a higher ZIKV
burden in low socioeconomic status (SES) areas. High seroprevalence, combined
with case data dynamics allowed estimates of the basic reproduction number R0 of
2.1 (CI, 1.8 to 2.5) at the onset of the outbreak and an effective reproductive num-
ber Reff of 1 in subsequent years. Our data corroborate ZIKV-associated congenital
disease and an association of low SES and ZIKV infection and suggest that popula-
tion immunity caused cessation of the outbreak. Similar studies from other areas will
be required to determine the fate of the American ZIKV outbreak.
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IMPORTANCE The ongoing American Zika virus (ZIKV) outbreak involves millions of
cases and has a major impact on maternal and child health. Knowledge of infection
rates is crucial to project future epidemic patterns and determine the absolute risk
of microcephaly upon maternal ZIKV infection during pregnancy. For unknown rea-
sons, the vast majority of ZIKV-associated microcephaly cases are concentrated in
northeastern Brazil. We analyzed different subpopulations from Salvador, a Brazilian
metropolis representing one of the most affected areas during the American ZIKV
outbreak. We demonstrate rapid spread of ZIKV in Salvador, Brazil, and infection
rates exceeding 60%. We provide evidence for the link between ZIKV and micro-
cephaly, report that ZIKV predominantly affects geographic areas with low socioeco-
nomic status, and show that population immunity likely caused cessation of the out-
break. Our results enable stakeholders to identify target populations for vaccination
and for trials on vaccine efﬁcacy and allow refocusing of research efforts and inter-
vention strategies.
KEYWORDS Zika virus, microcephaly, risk factors, serology, socioeconomic status
During 2016, the Zika virus (ZIKV) outbreak in Latin America and the Caribbean wasdeclared a public health emergency of international concern (1). Autochthonous
circulation of ZIKV is now reported across vast areas of Latin America (2, 3).
Many countries in the Americas have reported high rates of clinically suspected ZIKV
infections (2), but the proportion of laboratory-conﬁrmed cases remains low. Case
identiﬁcation is hindered by the clinical similarities between ZIKV and endemic dengue
virus (DENV) as well as Chikungunya virus (CHIKV) disease (4). Among the challenges in
laboratory testing is the low and short-lived presence of ZIKV in body ﬂuids (5).
Furthermore, detection of ZIKV-speciﬁc antibodies in tropical regions is ambiguous due
to cross-reactive antibodies elicited by previous infections with antigenically related
viruses, including the widespread DENV (4), limiting accurate diagnostic testing even
when using highly speciﬁc neutralization tests (6). In addition, asymptomatic courses in
an estimated 80% of ZIKV-infected individuals (7) make clinical cases an insensitive
measure of population-level exposure. Uncertainty about the ZIKV infection rate and
proportion of the population exposed has key implications for modeling the trajectory
of the American ZIKV outbreak (8, 9) and studies describing the etiology and frequency
of ZIKV-associated congenital disease (10, 11).
For unknown reasons, northeastern Brazil has reported the vast majority of cases of
ZIKV-associated microcephaly (12). Among the possible effect modiﬁers is the low
socioeconomic status (SES) of the northeastern states of Brazil, exempliﬁed by an
approximately 5- to 10-fold lower monthly household income compared to more-
afﬂuent regions of Brazil (13). As shown in Fig. 1, the northeastern state of Bahia is one
of the most underdeveloped Brazilian states according to the human development
index (HDI) provided by the United Nations Development Programme (UNDP). Bahia
was among the most ZIKV-affected regions in 2015 (14). However, the potential
cofactors for ZIKV-associated microcephaly and whether these cofactors may be asso-
ciated with low SES remain unclear.
Here, we investigate specimens sampled before, during, and after the current ZIKV
outbreak to reconstruct the temporal spread of ZIKV in Salvador, the capital of Bahia,
Brazil. We determine the infection rate of ZIKV in different subpopulations, explore its
etiologic role in congenital disease, and use a mathematical modeling approach to
project the trajectory of the ZIKV epidemic. Finally, we use a geographic information
system-based approach to identify location-speciﬁc differences of ZIKV exposure and
explore their associations with low SES.
RESULTS
This study comprised 910 individuals from Salvador, Brazil, representing four differ-
ent subpopulations. To assess the role of ZIKV in congenital disease, we collected
specimens from parturients from 25 November 2015 to 2 May 2016. These specimens
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included samples from 16 mothers of neonates with microcephaly and three neonates
with microcephaly for whom the mothers’ sera could not be obtained, as well as 255
mothers of neonates without microcephaly, including two neonates for whom the
mothers’ sera could not be obtained. To investigate the temporal spread of ZIKV and
to assess speciﬁcity of the serological tests, samples from 540 HIV-infected patients
were used. These specimens included stored samples collected between 12 January
2013 to 30 August 2015 and samples from patients who attended HIV outpatient
departments between 25 November 2015 to 28 May 2016. Finally, 55 tuberculosis
patients and 39 university employees were sampled from 12 January 2016 to 28 May
2016 to investigate the impact of SES on ZIKV exposure (Fig. 2A). All adult age groups
composing the general population of Salvador, Brazil, were represented in our study
(Fig. 2B), and the subpopulations included in this study comprised individuals whose
households were widely spread across urban Salvador (see Fig. S1 in the supplemental
material). The main assay used for serological testing was a commercially available
enzyme-linked immunosorbent assay (ELISA) relying on the recombinant NS1 antigen
of ZIKV (15, 16), because this assay was the only test certiﬁed for serological diagnostics
of ZIKV by the responsible Brazilian authority ANVISA (Agência Nacional de Vigilância
Sanitária) and thus available to us during this study (17). Conﬁrmatory testing con-
FIG 1 Ranking of Brazilian states according to the United Nations Development Programme. Longevity
(gray), income (orange) and education (red) indexes, and the human development index (blue) as the
geometric mean of the three aformentioned indexes. Data retrieved from Atlas Brazil, 2013 (http://www
.atlasbrasil.org.br/2013/). The northeastern state Bahia is shown in bold and red.
FIG 2 Serosurveys and distribution of specimens per age category. (A) Main research question, time span
of sampling, and specimens per subpopulation. (B) Distribution of specimens per age category. Only
specimens sampled for all subpopulations in 2015 to 2016 were included due to low Zika virus
prevalence in the preceding years. The numbers (n) of study participants for which age information was
available are given below the age categories. Age data for Salvador were retrieved from the 2010 census
(https://cidades.ibge.gov.br/brasil/ba/salvador/panorama).
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ducted in about half of the sera used in this study included plaque reduction neutral-
ization tests (PRNT) and an in-house ELISA relying on a recombinant envelope (E)
antigen of ZIKV (56), designed to be robust against unspeciﬁc reactivity by targeted
mutation of cross-reactive residues and preincubation of sera with heterologous anti-
gens of the four DENV serotypes.
ZIKV infection in parturients. A case-control study conducted in the neighboring
northeastern metropolis Recife, Brazil, suggested an etiologic role of ZIKV in congenital
disease (18). Consistent with these data, 18 of 19 parturients whose neonates were born
with microcephaly (termed microcephaly pregnancies) from Salvador, Brazil, showed
IgG antibodies against ZIKV (94.7%; 95% conﬁdence interval [CI], 73.5 to 99.9%),
compared to 69.3% of 257 non-microcephaly pregnancies using an NS1-based ELISA
(CI, 63.3 to 74.5%; Table 1 and Fig. 3A). The higher ZIKV seroprevalence in microcephaly
pregnancies compared to non-microcephaly pregnancies was statistically signiﬁcant
(P  0.017 by Fisher’s exact test; relative risk  1.4 [CI, 1.2 to 1.6]) and similar to ZIKV
infection in 80.0% of microcephaly pregnancies compared to 63.9% of controls in Recife
(18). Data from PRNT and the NS1 antigen ELISA were highly consistent (Table 1 and
Fig. 3A). Unfortunately, lack of adequate sera taken close to birth prevented determi-
nation of ZIKV-speciﬁc IgM in all newborns with microcephaly.
Temporal spread of ZIKV. Phylogenetic reconstructions have suggested that ZIKV
was introduced into the Americas during mid-late 2013 (14, 19). To assess whether the
projected time of introduction can be conﬁrmed by population-level antibody re-
sponses, we tested specimens from HIV-infected patients collected between 2013 and
2016. Retrospective specimens were available from routine attendance of HIV-infected
patients for viral load measurements and resistance genotyping within the Brazilian HIV
treatment program. Unfortunately, DENV-speciﬁc antibodies can cause false-positive
ZIKV test results even when using highly speciﬁc PRNTs (20). Comparison of titer
magnitudes between DENV and ZIKV PRNTs may support virological diagnostics of ZIKV
exposure in paired sera from cases of acute febrile illness. However, ZIKV and DENV
PRNT titers can range from 1:10 to about 1:100,000 in secondary ﬂavivirus infections
(20). DENV PRNTs are thus not an optimal solution to distinguish ZIKV from DENV
exposure in a population-based sample from an area that is hyperendemic for DENV.
TABLE 1 Serological test resultsa
Subpopulationb
Median age
(yr) (IQR)c
Total no. of
individuals
tested for
ZIKV by ELISA
ZIKV
IgM ZIKV IgG ZIKV PRNT CHIKV IgG DENV IgGd
n % n %
n/total
no. %
n/total
no. %
n/total
no. %
HIV patients
2013 36.7 (16.4) 96 0 0 7 7.3 7/96 7.3 52/84 61.9
2014 38.8 (17.8) 89 0 0 2 2.3 6/89 6.7 57/82 69.5
2015 36.6 (17.4) 92 2 2.2 16 17.4 1/92 1.1 46/68 67.6
Total retrospective 277
HIV patients 2016 44.7 (15.4) 263 2 0.8 139 52.9 31/61 50.8 22/263 8.4 88/110 80.4
MC pregnancies
2015–2016
28.5 (10.8) 19 1 5.3 18 94.7 14/15 93.3 3/19 15.8 0/1 0
Non-MC pregnancies
2015–2016
28.9 (10.9) 257 1 0.4 178 69.3 114/171 66.6 15/257 5.8 52/69 75.4
Tuberculosis patients
2016
45.1 (22.2) 55 2 3.6 47 85.5 14/20 70 4/55 7.3 8/8 100
University employees
2016
33.8 (12.3) 39 2 5.1 19 48.7 14/32 43.8 3/39 7.7 8/18 44.4
Total 2015–2016 633 8 1.3 401 63.3 187/299 62.5 47/633 7.4 156/206 75.7
Total study 910
aThe number of specimens (n) and percentage of specimens positive for antibodies against Zika (ZIKV), Chikungunya (CHIKV), or dengue (DENV) virus in ELISA or
plaque-reduction neutralization test (PRNT) are shown.
bMC, microcephaly.
cInterquartile range (IQR) shown in parentheses in the table.
dIncluding only ZIKV-negative specimens due to cross-reactivity of the DENV ELISA with ZIKV antibodies.
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Therefore, the sera from HIV-infected patients collected over 4 years were tested for
ZIKV-speciﬁc IgG using an NS1 antigen ELISA and in parallel an E-antigen competitive
ELISA. Both ELISAs yielded highly congruent results (Fig. 3B). ZIKV IgG seroprevalence
increased from 4.2 to 7.3% in 2013 to 2014 (CI, 1.3 to 9.1%) to 17.4% in 2015 (CI, 10.9
to 26.5%) and to 43.0 to 52.9% in 2016 (CI, 37.1 to 58.8%; Fig. 3B and Table S1). The
signiﬁcant increase in seroprevalence (2  127.7 and P  0.001 with the NS1 antigen
ELISA and 2  90.6 and P  0.001 with the E-antigen competitive ELISA) corroborated
the fast ZIKV spread in Salvador, Brazil, during 2015 to 2016 and suggested the
reliability of both ELISAs in an area that is hyperendemic for DENV, as illustrated by 61.9
to 80.4% of sera reactive for DENV during 2013 to 2016 (Fig. 3B and Table 1). The
signiﬁcantly lower numbers of ZIKV IgG detections in 2013 to 2014 may correspond to
the initial phase of ZIKV introduction into Salvador.
Patterns of ZIKV spread in Salvador, Brazil. In northeastern Brazil, low socioeco-
nomic conditions are major determinants of developing tuberculosis (21). To obtain
preliminary evidence for ZIKV infection rates in different social strata within Salvador,
Brazil, we therefore analyzed 55 low-SES patients treated for active tuberculosis (did not
graduate from college, most patients without complete secondary schooling) and 39
healthy university employees (most with college education, all completed secondary
schooling). As shown in Fig. 3C, signiﬁcantly more tuberculosis patients (85.5%; CI, 73.6
to 92.7%) than university employees (48.7%; CI, 33.9 to 63.8%) showed ZIKV-speciﬁc
antibodies (2 14.7; P 0.0001) using the NS1 antigen ELISA. When only PRNT results
were considered, the difference in seroprevalence between these two groups was
similar to that of the NS1-based analysis and statistically signiﬁcant, albeit at a lower
signiﬁcance level (2  4.48; P  0.044). Similar to a study demonstrating higher DENV
exposure in low-SES strata of the neighboring northeastern metropolis Recife prior to
FIG 3 ZIKV seroprevalence and reported cases. (A) ZIKV, CHIKV, and DENV seroprevalence in parturients. Non-microcephaly pregnancies (PRG)
(n  257 for ZIKV IgG and CHIKV IgG and n  69 for DENV IgG); microcephaly pregnancies (MC) (n  19 for ZIKV IgG and CHIKV IgG and n 
0 for DENV IgG). (B) ZIKV, CHIKV, and DENV seroprevalence in HIV-positive patients from 2013 (n  96 for ZIKV IgG and CHIKV IgG and n  52
for DENV IgG), 2014 (n  89 for ZIKV IgG and CHIKV IgG and n  57 for DENV IgG), 2015 (n  92 for ZIKV IgG and CHIKV IgG and n  46 for
DENV IgG), and 2016 (n  263 for ZIKV IgG and CHIKV IgG and n  110 for DENV IgG). (C) ZIKV, CHIKV, and DENV seroprevalence in tuberculosis
patients (TBC) (n  55 for ZIKV IgG and CHIKV IgG and n  8 for DENV IgG) and university employees (UNI) (n  39 for ZIKV IgG and CHIKV IgG
and n  20 for DENV IgG). (D) ZIKV, CHIKV, and DENV seroprevalence in all 633 samples from 2016. The bars in panels A to D depict 95%
conﬁdence intervals. (E) Seroprevalence per age group for ZIKV IgG, CHIKV, and DENV in 633 samples from 2016. (F) Reported Brazilian cases of
acute exanthematic disease in Salvador and Bahia until epidemiological week 22 in 2017. The months are indicated by capital ﬁrst letter.
Zika Virus Seroprevalence in Brazil ®
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the introduction of ZIKV (22), DENV seroprevalence was signiﬁcantly higher in tuber-
culosis patients at 100% (CI, 70.7 to 100%) than in university employees at 44.4% (CI,
24.5 to 66.3%; 2  7.22; P  0.007). This suggested more common exposure to
arboviruses in low-SES strata in Salvador and validity of the comparison of ZIKV
exposure in these subpopulations as proxy variables for different SESs.
Combining all study groups, ZIKV seroprevalence in Salvador, Brazil, in 2016 was
63.3% (CI, 59.4 to 66.8%) according to an NS1 antigen ELISA and 62.5% (CI, 56.9 to
67.8%) according to PRNT. Seroprevalence estimates according to the NS1 antigen
ELISA and PRNT were thus near-identical (Fig. 3D and Table 1), even though NS1
antigen ELISA and PRNT results varied in 14.7% of individual specimens (Table 2).
Despite its recent introduction, the seroprevalence of ZIKV thus almost reached that of
the endemic DENV at 75.7% (CI, 69.4 to 81.1%), although DENV seroprevalence was still
signiﬁcantly higher (2  10.1; P  0.001; Fig. S1 and Table 1). The high DENV
seroprevalence in Salvador, Brazil, corresponded to a previous study reporting around
80 to 90% population-level DENV seroprevalence in northeastern Brazil before the
introduction of ZIKV (22). No signiﬁcant differences in ZIKV seroprevalence between
male and female study participants were observed within subpopulations (Table S2).
Finally, all age groups in this study showed similar ZIKV antibody detection rates (2 
6.6; P  0.4; Fig. 3E and Table S3), suggesting widespread rapid transmission with no
age-related variation in exposure. These data suggested rapid spread of ZIKV within
Salvador and were consistent with the age distribution observed during the 2007 Yap
ZIKV outbreak (4).
Differential spread of ZIKV and CHIKV. The emergence of CHIKV in the Americas
parallels that of ZIKV spatiotemporally with the introduction and transcontinental
spread in 2013 to 2014, and both viruses use Aedes mosquitos as vectors (23–25).
However, CHIKV seroprevalence remained consistently low in HIV patients during 2013
to 2016 at 1.1 to 8.4% (2  5.9; P  0.12; Fig. 3B, light gray), reaching an overall
seroprevalence of 7.4% across all study groups in 2016 (CI, 5.6 to 9.8%; Fig. 3D and
Table 1). Our CHIKV seroprevalence estimate was consistent with that of an indepen-
dent study from Salvador, Brazil (26). Our data thus suggested an accelerated dissem-
ination of ZIKV compared to CHIKV in Salvador, Brazil.
Low rate of acute ZIKV infections in 2016. Cases of acute exanthematic disease,
the lead symptom of ZIKV infection in adults, reported in the Bahia state within the
Brazilian surveillance system SINAN were retrieved and compared to our observations.
Of the 67,454 cases reported in Bahia during 2015, 35,261 originated from Salvador
(52.3%) (Fig. 3F, blue line). The ﬁrst year of the ZIKV outbreak in Bahia was thus
concentrated in Salvador. In contrast, in 2016, 59,054 ZIKV cases were reported all over
Bahia (Fig. 3F, red line) of which only 928 cases originated from Salvador (1.6%). To see
whether the decline of notiﬁed cases from Salvador in 2016 could be conﬁrmed by
laboratory tests, we tested all specimens for ZIKV RNA and ZIKV IgM. None of the
specimens tested positive for ZIKV RNA. In agreement with the high ZIKV seropreva-
lence from 2015 onwards, IgM-based incidence was detected only in 2015 (2.2%; CI, 0.1
to 8.0%) and 2016 (1.3%; CI, 0.6 to 2.5%) (Fig. 3F, arrows). Until mid-2017, the number
of reported cases remained consistently low from both Salvador and the state of Bahia.
This suggests that the outbreak ceased due to the lack of acute cases.
Modelling the trajectory of the epidemic in Salvador, Brazil. To test whether
population immunity would limit future cases in Salvador, Brazil, we ﬁtted a mathe-
matical model of ZIKV transmission jointly to the independent case notiﬁcation data
from Salvador and the seroprevalence results from our study. Our results showed that
the observed data are consistent with a single-year continuous epidemic that began
early in 2015 and declined toward the end of 2015 (Fig. 4A and B).
The estimated basic reproduction number (R0) for ZIKV was 2.1 (CI, 1.8 to 2.5) at the
onset of the outbreak with, on average, 2.0% (CI, 1.8 to 2.2%) of ZIKV infections
reported in the national surveillance system. Projecting the model forward into 2016
suggested a continued decline in transmission despite the return of peak arbovirus
Netto et al. ®
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season. Due to the lack of susceptible individuals, the effective reproductive number
(Reff) was not predicted to exceed one in subsequent years, a condition required for
another ZIKV epidemic wave (Fig. 4C and D).
Impact of SES. To further investigate the impact of low SES on ZIKV infection rates,
the home addresses of study participants were georeferenced onto 147 spatial units
classiﬁed into human development units (HDUs) according to sociodemographic char-
acteristics (Fig. 5A and Fig. S1). HDUs showing ZIKV-positive cases represented signif-
icantly lower SES in 65 (32.2%) of 201 indicators (Table S4). The latter included all 56
available population indicators, as well as less regular garbage recollection, a higher
proportion of child and youth labor, inferior schooling, and lower income in ZIKV-
positive HDUs (Fig. 5B shows the most signiﬁcant indicators per category). No signiﬁ-
cant differences were observed regarding the occurrence of microcephaly in HDUs.
Logistic regression analyses were conducted to identify which SES-associated indicators
were most associated with ZIKV-positive HDUs. However, the high degree of multicol-
linearity between sociodemographic indicators prevented model convergence.
Finally, a nested case-control approach was conducted to investigate whether
low-SES-associated indicators inﬂuenced the occurrence of microcephaly indepen-
dently of ZIKV infection. To that end, six pregnant women matched for age (within
2 years) for each of 12 microcephaly cases living in HDUs within metropolitan Salvador,
Brazil, were chosen, and the sociodemographic indicators of the respective HDUs were
attributed to cases and controls (Fig. 5C). Only the ZIKV serostatus differed signiﬁcantly
between cases and controls (2  4.1; P  0.043), in contrast to the sociodemographic
indicators.
DISCUSSION
Here we present the results of what is, to the best of our knowledge, the ﬁrst
arboviral seroprevalence survey in Latin America since the beginning of the Zika
epidemic. We demonstrate a high ZIKV infection rate of about 63% in Salvador, the
third-largest Brazilian city with about 2.7 million inhabitants in northeastern Brazil. This
rate was comparable to the 66 to 73% seroprevalence found on Yap, Micronesia, and
French Polynesia, although these ZIKV outbreaks occurred in 10- to 300-fold smaller
FIG 4 Transmission model and projected trajectory of the Zika epidemic in Salvador, Brazil. (A) Model
ﬁt to ZIKV incidence in Salvador. The red circles show the reported ZIKV cases. The black line shows the
median model estimate. The shaded regions depict the interquartile range and 95% CI. (B) ZIKV
seroprevalence over time in the study population (n  633). The black line shows the median model
estimate. The shaded regions depict the interquartile range (IQR) and 95% CI. The red circle shows the
observed proportion of seropositive individuals. (C) Estimated seasonal variation in ZIKV transmission. (D)
Estimated change in effective reproduction number over time.
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island populations (10, 27). The similar seroprevalence rates suggest effective ZIKV
spread irrespective of different geographic settings.
The reasons for the differential spread of ZIKV and CHIKV in Salvador, Brazil, remain
unclear. Hypothetically, the faster spread of ZIKV might be associated with viral
properties affecting transmission. However, a putative replicative advantage of ZIKV
over CHIKV in Brazilian Aedesmosquitos is not warranted by vector competence studies
(28, 29). Similarly, increased availability of ZIKV to mosquito vectors during feeding on
viremic humans is unlikely, since viral loads can be considerably higher in CHIKV
infections than in ZIKV infections (5). An alternative explanation may include ampliﬁ-
cation of CHIKV in sylvatic cycles prior to its putative introduction into urban cycles in
Salvador, Brazil. However, whether CHIKV may enter a sylvatic cycle in the Americas
remains to be determined (30). Finally, whereas sexual transmission of ZIKV may have
contributed to its initial spread, the predominant route of transmission likely remains
vector-borne, opposing a relatively faster spread of ZIKV due to sexual transmission
(31). So far, the most plausible explanation may include differences in the geospatial
introduction of CHIKV and ZIKV within northeastern Brazil. Indeed, the main foci of
CHIKV infections in the Brazilian state of Bahia were initially centered in the hinterland,
whereas ZIKV may have been directly introduced to the densely populated Atlantic
coast, including Salvador, facilitating efﬁcient spread in relatively larger, more con-
nected human populations (32, 33).
Our modeling estimates of the basic reproduction number R0 were lower than in
estimates for Paciﬁc island populations (34) but consistent with recent estimates from
several independent studies (8, 31, 35). Moreover, our data and modeling projections
FIG 5 Association of socioeconomic status and ZIKV exposure. (A) Maps showing Brazil, the state of Bahia, metropolitan Salvador, and sample distribution onto
human development units (HDUs). (B) Sociodemographic indicators differing signiﬁcantly between ZIKV-positive and ZIKV-negative HDUs. Boxplots show
medians, interquartile range (box length), outliers (circles), and extreme values (squares). Values that are signiﬁcantly different are indicated by bars and asterisks
as follows: *, P  0.05; **, P  0.01. (C) Distribution of samples used for nested case-control study. ZIKV-positive and -negative cases and microcephaly
pregnancies (stars; n  11) are shown. One additional case was outside the area shown in the map. Seven other cases were insufﬁciently georeferenced. Due
to geographic proximity of home adresses of some controls, not all 72 controls are visible.
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suggest that ZIKV was able to reach the critical population immunity threshold within
a single year and that community protective immunity could restrict ZIKV spread in this
area until susceptible individuals are replaced by birth or migration. This ﬁnding is
consistent with the near-complete lack of reported cases from Salvador, Brazil, since
2016 and with previous model-based projections that predicted the cessation of the
current Latin American outbreak within the next few years (8). The limitation of ZIKV
spread due to community protective immunity is probably analogous to CHIKV, be-
cause both viruses show limited antigenic variability. Consistent with our data, CHIKV
infection rates exceeding 60% have been associated with the cessation of outbreak
activity (36). In Africa and probably in Asia as well, CHIKV can emerge cyclically from
nonhuman primate reservoirs upon replenishment of sufﬁcient numbers of susceptible
individuals (36). Whether ZIKV can establish a sylvatic transmission cycle in Latin
America thus requires urgent investigation (37).
The high rate of ZIKV-positive mothers of microcephaly cases in our study substan-
tiates the recent case-control study from Recife, Brazil (18) in identifying ZIKV as the
cause of the surge in microcephaly cases in northeastern Brazil. Additionally, our data
enable more precise risk estimates of congenital ZIKV disease. In the absence of
serological data, the risk of fetal microcephaly upon maternal ZIKV infection in the ﬁrst
trimester has previously been modeled across a seroprevalence interval spanning 10 to
80% (10). According to that study (10), the 63% seroprevalence rate found in this study
implies a risk of fetal microcephaly in Bahia of about 1% during the ﬁrst trimester. This
risk is analogous to the 0.95% risk modeled for French Polynesia assuming a similar
ZIKV infection rate of 66% (27) and similar to the 1.7% prevalence of microcephaly
found in ZIKV-infected mothers in a cohort study in French Guiana (38).
Finally, our results suggest an impact of low SES on the probability of ZIKV infection.
Whether the increased ZIKV infection rate correlates with increased risk of microcephaly
remains to be determined, but it is in line with anecdotal evidence from the Brazilian
Ministry of Health (39). Our data correspond to a previous study demonstrating higher
DENV infection rates in lower social strata from northeastern Brazil (22). However, other
etiologic factors associated with low SES remain to be determined in large prospective
epidemiological studies, including detailed assessments of individual-level determi-
nants of SES, exhaustive assessments of infectious and noninfectious causes of con-
genital malformations, clinical symptoms other than microcephaly, and differences in
access to abortion practice between different social strata in Latin America, which may
cause a relatively higher incidence of neonates with malformations in lower social strata
because higher social strata may have a relatively easier access to antenatal care,
including imaging techniques allowing premature identiﬁcation of malformations lead-
ing to abortion practices (40–42). Of note, our data may imply that individuals and areas
with a relatively higher SES may represent a potential reservoir for focal reemergence
of ZIKV in Salvador, Brazil. However, whether high-SES strata may represent a sufﬁcient
community size to allow ZIKV resurgence in Salvador remains to be determined.
The strengths of our study include the large sample from different subpopulations
that can identify key variations in transmission rates, the longitudinal analysis of
patients before, during, and after the Zika outbreak, the multidisciplinary approach
allowing insights into geospatial and sociodemographic factors affecting ZIKV expo-
sure, and the comparison of seroprevalence of multiple arboviruses using a range of
laboratory tests. A principal limitation of this study is the availability-based sample of
individuals which may not be representative of the general population. However, the
age distribution of individuals across the pooled samples was comparable to that of
the general population, and infection rates in pregnant women were comparable to the
overall seroprevalence from the combined subpopulations. Finally, seroprevalence
results were comparable to (i) the independent case data from Salvador, Brazil, (ii)
previous ZIKV seroprevalence surveys in other areas, and (iii) the seroprevalence results
for DENV and CHIKV in other settings, suggesting that our study is robust despite our
nonsystematic sampling design. Importantly, our seroprevalence data enabled an
estimate of R0 that was highly consistent with estimates from other studies not
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containing serological information from the current American outbreak (8, 31, 35). The
similarities between those modeling approaches and our data were thus supportive of
the appropriateness of our data set. However, a principal challenge to our study arises
from the high levels of cross-reactivity of antibodies elicited by different ﬂaviviruses in
serological tests, limiting the ability to obtain unequivocal serological results (43).
Previous studies assessing the speciﬁcity of the NS1-based ELISA we used in our study
yielded conﬂicting results (15, 44). However, the majority of studies aiming at test
validation investigated patients with acute febrile illness and included only a few or no
sera from individuals living in areas where DENV is endemic, limiting the ability to
extrapolate results from those studies to our study population. Recent studies investi-
gating asymptomatic blood donors from Martinique and Cameroon suggested appli-
cability of the NS1-based ELISA, despite a high DENV burden in these areas (45, 46).
Furthermore, our NS1-based ELISA results were largely congruent with PRNT-based
analyses conducted within subpopulations. Of note, recent data suggest that PRNT
speciﬁcity in late convalescent-phase sera may be high enough to retain its utility as a
tool for population-level ZIKV serosurveillance (47). In sum, our seroprevalence data for
samples collected during four consecutive years, before and during the dissemination
of ZIKV in Salvador, Brazil, using two different ZIKV antigens for ELISA, and conﬁrmation
of ELISA results by PRNT strongly suggest that our data are valid despite the limita-
tions of any serological investigation of ZIKV-speciﬁc antibody responses in areas in
which other ﬂaviviruses are hyperendemic. Of note, applicability of the NS1-based
ELISA in our population-based study does not translate into a recommendation of its
usage for patient diagnostics, which may require further validation and innovative tools
that are not yet broadly available, such as a recently published monoclonal antibody-
based competitive ELISA (48).
In summary, our data demonstrate high ZIKV infection rates in a Brazilian setting and
suggest that the ZIKV outbreak ceased due to community protective immunity. Pre-
vention of congenital ZIKV disease may need to incorporate responses to low SES-
associated cofactors in addition to pathogen-oriented measures. Further studies of
outbreak settings are urgently needed outside northeastern Brazil to determine
whether such explosive and underrecognized ZIKV epidemics have also occurred.
Ideally, these studies should include sera from neonates with congenital disease and
their mothers sampled early during pregnancy, as well as specimens from adults
suffering from severe ZIKV disease to identify whether determinants of severe ZIKV
disease are shared among congenital and adult infections.
MATERIALS AND METHODS
Ethical clearance, sampling sites, and sample storage. Sampling and testing were approved by
the Federal University of Bahia (UFBA) research ethics board Climério de Oliveira under protocol
1.408.499. HIV patients were sampled at the UFBA teaching hospital. Tuberculosis patients were sampled
at the José Silveira Foundation-Brazilian Institute for Investigation of Tuberculosis. Pregnant women were
sampled at the time of delivery at the UFBA maternity hospital Climério de Oliveira. All patients attended
during the study period accepted participation in the protocol. Microcephaly was diagnosed when the
measurement of the cephalic circumference was 2 standard deviations below that of the corresponding
gestational age, based on intergrowth charts from the World Health Organization in addition to clinical
and imaging data as recommended (49).
Laboratory analyses. All samples were analyzed for viral RNA using real-time reverse transcription-
PCR (RT-PCR) assays for ZIKV (5). Serological testing was performed by using enzyme-linked immunosor-
bent assays (ELISAs) for ZIKV IgM/IgG (Euroimmun, Lübeck, Germany) (NS1 antigen), DENV IgG (Euroim-
mun) (full virus lysates), and CHIKV IgG (Euroimmun) (recombinant structural protein) according to the
manufacturer’s instructions. Brieﬂy, sera diluted 1:101 in sample buffer were added to the wells and
allowed to react for 60 min at 37°C. Before IgM detection, sera were preincubated with sample buffer
containing IgG/rheumatoid factor absorbent (Euroimmun) to remove class IgG antibodies. Bound
antibodies were detected by applying goat anti-human IgM peroxidase conjugate or rabbit anti-human
IgG peroxidase conjugate for 30 min at room temperature. The competitive ELISA using a mutant E
protein of ZIKV was conducted according to reference 50 for DENV and is described in detail elsewhere
(56). Brieﬂy, the quadruple mutant E protein from ZIKV (strain H/PF/2013, E-protein amino acid residues
1 to 406, GenBank accession no. KJ776791) bearing the point mutations T76A, Q77G, W101R, and L107R
was expressed in Drosophila S2 cells. Serum samples (diluted 1:100 in 100 l blocking solution) were
preincubated with 2 g/sample of mutant DENV E proteins (mixture of the four DENV serotypes [50] for
1 h to remove DENV antibodies and/or cross-reacting antibodies). Following the preincubations, samples
Zika Virus Seroprevalence in Brazil ®
November/December 2017 Volume 8 Issue 6 e01390-17 mbio.asm.org 11
 
m
bio.asm
.org
 o
n
 D
ecem
ber 4, 2017 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
were transferred to 96-well plates coated overnight with ZIKV mutant E protein (150 ng/well), and the
assay was completed following standard ELISA procedures.
Due to 100% cross-reactivity of ZIKV-speciﬁc IgG antibodies with the DENV ELISA antigen (43), only
clearly ZIKV-negative specimens were used for assessments of DENV seroprevalence (Fig. S2). Plaque
reduction neutralization tests (PRNTs) for ZIKV (51) were used for conﬁrmation in 199 ELISA-positive
specimens and 100 ELISA-negative specimens from 2016 for which sufﬁcient serum volumes were
available (Table 2). All sera were heat inactivated (56°C, 30 min) prior to neutralization testing. Two
microliters of serum was diluted in 1% Dulbecco modiﬁed Eagle medium (DMEM) at 1:25, 1:250, 1:2,500,
and 1:25,000 and incubated at 37°C for 60 minutes with 50 plaque-forming units (PFU) of ZIKV outbreak
strain H/PF/2013 resurrected from subgenomic cDNA fragments transfected into BHK cells as described
previously (52). A second incubation was done at 37°C for 60 min in 12-well plates, followed by an
agarose-DMEM (containing 2% fetal calf serum and 0.6% ﬁnal agarose concentration) overlay. Cells were
incubated for 4 days before formaldehyde ﬁxation, staining with crystal violet, and plaque counting.
Serum titers reducing ZIKV PFU by 50% compared to controls in any dilution were considered positive.
NS1 ELISA ratios of sera tested by PRNT did not differ signiﬁcantly from those not tested by PRNT (P 
0.20 by t test).
Georeference and demographic data. The home addresses of study participants were georefer-
enced onto spatial units (human development units [HDUs]) according to census data from the Instituto
Brasileiro de Geograﬁa e Estatística, dividing the metropolitan region of Salvador, Brazil, into socioeco-
nomically homogenous areas, taking into account a minimum of 400 permanent households at a ﬁrst
classiﬁcation step, and socioeconomic homogeneity at a second step, provided within the Brazilian
Human development atlas (http://www.atlasbrasil.org.br/2013/pt/consulta/) from the United Nations
Development Programme (UNDP). HDUs are described by seven different categories: population, de-
mography, housing, labor, education, income, and vulnerability. Maps were generated using ArcGIS 10.3
(ESRI, Redlands, CA, USA).
Statistical analyses. Statistical analyses included 2 and Fisher’s exact tests for comparisons of
seroprevalence rates (EpiInfo V7.2; http://www.cdc.gov/epiinfo), two-tailed Mann-Whitney U tests for
comparisons of sociodemographic indicators and logistic regression with stepwise backward elimination
of variables for multivariate analyses (SPSS V23; IBM, Ehningen, Germany), done on one variable per HDU
category, selected according to highest P values in bivariate comparisons. Diagnostic test parameters
were calculated using OpenEpi (http://www.openepi.com).
Transmission dynamic modeling. ZIKV outbreak dynamics were analyzed using a susceptible-
exposed-infectious-recovered (SEIR) model. The vector population was not explicitly taken into account,
but variation in mosquito numbers was modeled through annual seasonal forces acting on the trans-
mission rate. The model was implemented in a Bayesian framework using the LibBi library via the RBi and
RBi.helpers packages (53–55). The model was jointly ﬁtted to reported ZIKV incidence data from Salvador,
Brazil, from the beginning of January 2015 to the end of October 2015 and the proportion of individuals
(401/633) who were seropositive to ZIKV in 2016. Incidence was ﬁtted using a Poisson likelihood with
overdispersion and approximated with a truncated Gaussian distribution, and seroprevalence was ﬁtted
using a binomial likelihood. Informative prior probability distributions were used for the delay between
infection and infectiousness (the sum of the mosquito-to-human generation time and the intrinsic
incubation period) centered around 17.8 days, and the infectious period in humans centered around
4.7 days, respectively (8), and for the peak of seasonality in mid-May based on dengue transmission
dynamics in Salvador, Brazil. Uniform prior probability distributions were used for the amplitude of
seasonality, proportion of cases reported, and basic reproduction number, R0. Regularizing prior prob-
ability distributions were used for the initial numbers of infected and overdispersion of reporting. All
model parameters were estimated using Markov chain Monte Carlo. Full prior and posterior probability
distributions are shown in Fig. S3.
Data availability. A document containing the code necessary to reproduce the modeling results is
provided in Data Set S1.
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